Developing Human Brain NSPC Isolation by Surface-Marker FACS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for isolating and characterizing neural stem and progenitor cells (NSPCs) from human brain tissue lack precision and purity, particularly for nuanced cell types like ventricular and outer radial glia, due to the heterogeneity of cell populations and the lack of rigorous characterization using cell-surface markers.
Innovation Solution
Methods for identifying and isolating NSPC populations based on specific cell-surface marker immunophenotypes, using antibody panels and fluorescence-activated cell sorting (FACS) to enrich for distinct cell types such as ventricular radial glia, outer radial glia, astrocytes, and oligodendrocyte precursor cells, with purity assessment through transcriptomic correlation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional isolation methods are used, then cell population can be obtained, but purity and precision are insufficient due to heterogeneity
Solution Approach 1:
The patent applies parameter changes by utilizing multiple cell surface markers (CD133, CD24, THY1, PDGFRA, EGFR) with specific expression patterns to define distinct NSPC populations. By changing the parameters of marker combination and expression levels, the method achieves high-purity isolation of specific cell types such as ventricular radial glia (CD133+CD24-THY1-/loPDGFRA-EGFR+) and outer radial glia (CD133+CD24-THY1-/loPDGFRA-EGFR-), resolving the contradiction between isolation purity and method complexity.
2Measurement precision
If cell surface markers are used for isolation, then specific cell populations can be enriched, but rigorous characterization is lacking
Solution Approach 1:
The patent applies segmentation by dividing the heterogeneous NSPC population into distinct subpopulations based on specific marker combinations. Each population (ventricular radial glia, outer radial glia, astrocytes, oligodendrocyte precursors) is segmented and characterized by a unique immunophenotypic signature, enabling precise identification and functional characterization of each cell type.
3Productivity
If FACS sorting is used, then cell enrichment is achieved, but functional characterization remains challenging
Solution Approach 1:
The patent applies parameter changes by defining specific marker expression patterns that correlate with functional characteristics. For example, CD133+CD24-THY1-/loPDGFRA-EGFR+ cells are identified as ventricular radial glia with neurosphere-forming capacity, while CD133+CD24-THY1-/loPDGFRA-EGFR- cells are outer radial glia with different functional properties. This parameter-based classification enables both efficient enrichment and functional characterization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high-purity isolation of NSPC populations that retain functional characteristics, enabling robust engraftment and differentiation into specific neural lineages, with enhanced neurosphere formation capabilities and site-specific migration.
Implementation Method 1
contacting the single cells with a panel of antibodies thereby producing labeled single cells
Implementation Method 2
using antibody panels and fluorescence-activated cell sorting (FACS) to enrich for distinct cell types
Data Source
AI summary
Methods for identifying, isolating and enriching neural stem and progenitor cells (NSPC) such as ventricular radial glia, outer radial glia, astrocytes, pre-oligodendrocyte precursor cells, oligodendrocyte precursor cells, oligodendrocytes, early excitatory neurons, late excitatory neurons, bipotent glial progenitors, and inhibitory neurons are provided. These methods find use in transplantation, to eliminate specific cell subsets, for experimental evaluation, as a source of lineage and cell-specific products, and the like, for example for use in treating human disorders of the central nervous system (CNS).


